Xyzal Dosage/Direction for Use

The film-coated tablet must be taken orally, swallowed whole with liquid and may be taken with or without food. It is recommended to take the daily dose in one single intake.
Duration of use: Intermittent allergic rhinitis (symptoms <4 days/week or for less than 4 weeks a year) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear.
In case of persistent allergic rhinitis (symptoms >4 days/week or for more than 4 weeks a year), continuous therapy can be proposed to the patient during the period of exposure to allergens.
There is clinical experience with the use of levocetirizine for treatment periods of at least 6 months. In chronic urticaria and chronic allergic rhinitis, there is clinical experience of use of cetirizine (racemate) for up to one year.
Adults and adolescents 12 years and above: Levocetirizine dihydrochloride, 5 mg, film-coated tablet: The daily recommended dose is 5 mg (1 film-coated tablet).
Children: Children aged 6 to 12 years: Levocetirizine dihydrochloride, 5 mg, film-coated tablet: The daily recommended dose is 5 mg (1 film-coated tablet).
Elderly: Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see Renal impairment as follows).
Renal impairment: The dosing intervals must be individualised according to renal function. Refer to the table as follows and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the formula as follows: (see equation and table).

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and his body weight.
There is no specific data for children with renal impairment.
Hepatic impairment: No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of the dose is recommended (see Renal impairment previously mentioned).
Route of Administration: For oral use.